from the Neuro board
That's the thing. I wonder how many people are worried versus how many are in denial. Management has to do their job in telling us we are a lean sales force and to continue staying focused. The reality is they dont know who will be hit with the reduction. The Israelis will analyze each area to decide. Now if Copaxone goes generic, I don't think Copaxone will go away over night. Analysts state it will earn 200 million by 2019. Laquinimod, if it meets it's primary end points, will not be a blockbuster. It will not replace Copxone. Teva being sold to another company, makes sense.